Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 12, 2016, Pages 3020-3028

  Yu, Ting Wei ^a,b   Chueh, Ho Yen ^a,b   Tsai, Ching Chou ^a,c   Lin, Cheng Tao ^a,b   Qiu, Jiantai Timothy ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

cancer vaccine; cytotoxic T cells; GM CSF; immunotherapy

Indexed keywords

ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 15; INTERLEUKIN 2; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT;

BONE METASTASIS; CANCER THERAPY; CHEMOTHERAPY; DISEASE COURSE; GENE SYNTHESIS; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; PROTEIN EXPRESSION; RADIOTHERAPY; REVIEW; SURVIVAL RATE; ANIMAL; ANIMAL MODEL; CLINICAL TRIAL (TOPIC); GENETICS; IMMUNOLOGY; PRECLINICAL STUDY;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MODELS, ANIMAL;

EID: 85007488651     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1221551     Document Type: Review

References (87)

1. Kaushansky KOHP, Hart CE, Forstrom JW, Hagen FS. Role of carbohydrate in the function of human granulocyte-macrophage colony-stimulating factor. Biochemistry 1987; 26:4861-7; PMID:3499177
2. Cebon J, Nicola N, Ward M, Gardner I, Dempsey P, Layton J, Dührsen U, Burgess AW, Nice E, Morstyn G. Granulocyte-macrophage colony stimulating factor from human lymphocytes. The effect of glycosylation on receptor binding and biological activity. J Biol Chem 1990; 265:4483-91; PMID:2155231
3. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8:533-44; PMID:18551128; http://dx.doi.org/10.1038/nri2356
4. Mathias B, Szpila BE, Moore FA, Efron PA, Moldawer LL. A review of GM-CSF therapy in sepsis. Medicine 2015; 94:e2044; PMID:26683913; http://dx.doi.org/10.1097/MD.0000000000002044
5. Chang DZ, Lomazow W, Joy Somberg C, Stan R, Perales M-A. Granulocyte-macrophage colony stimulating factor:An adjuvant for cancer vaccines. Hematology 2004; 9:207-15; PMID:15204102; http://dx.doi.org/10.1080/10245330410001701549
6. Fleetwood AJ, Cook AD, Hamilton JA. Functions of granulocyte-macrophage colony-stimulating factor. 2005; 25:405-28; PMID:16167889
7. Gentile LF, Cuenca AG, Efron PA, Ang D, McKinley BA, Moldawer LL, Moore FA. Persistent inflammation and immunosuppression:A common syndrome and new horizon for surgical intensive care. J Trauma Acute Care surg 2012; 72:1491-501; PMID:22695412; http://dx.doi.org/10.1097/TA.0b013e318256e000
8. Landelle C, Lepape A, Voirin N, Tognet E, Venet F, Bohé J, Vanhems P, Monneret G. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med 2010; 36:1859-66; PMID:20652682; http://dx.doi.org/10.1007/s00134-010-1962-x
9. Reith W, LeibundGut-Landmann S, Waldburger J-M. Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol 2005; 5:793-806; PMID:16200082; http://dx.doi.org/10.1038/nri1708
10. Hotchkiss RS, Moldawer LL. Parallels between cancer and infectious disease. N Engl J Med 2014; 371:380-3; PMID:25054723; http://dx.doi.org/10.1056/NEJMcibr1404664
11. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, et al. Granulocyte–macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression. Am J Respir Critl Care Med 2009; 180:640-8; PMID:19590022; http://dx.doi.org/10.1164/rccm.200903-0363OC
12. Volk HD RP, Docke WD. Clinical aspects:from systemic inflammation to ‘immunoparalysis’. Chem Immunol 2000; 74:162-77; PMID:10608087; http://dx.doi.org/10.1159/000058753
13. Orozco H, Arch J, Medina-Franco H, Pantoja JP, González QH, Vilatoba M, Hinojosa C, Vargas-Vorackova F, Sifuentes-Osornio J. Molgramostim (gm-csf) associated with antibiotic treatment in nontraumatic abdominal sepsis:A randomized, double-blind, placebo-controlled clinical trial. Arch Surg 2006; 141:150-3; PMID:16490891; http://dx.doi.org/10.1001/archsurg.141.2.150
14. Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009; 5:554-9; PMID:19798030; http://dx.doi.org/10.1038/nrrheum.2009.178
15. Wicks IP, Roberts AW. Targeting GM-CSF in inflammatory diseases. Nat Rev Rheumatol 2016; 12:37-48; PMID:26633290; http://dx.doi.org/10.1038/nrrheum.2015.161
16. Bischof RJ, Zafiropoulos D, Hamilton JA, Campbell IK. Exacerbation of acute inflammatory arthritis by the colony-stimulating factors CSF-1 and granulocyte macrophage (GM)-CSF:evidence of macrophage infiltration and local proliferation. Clin Exp Immunol 2000; 119:361-7; PMID:10632676; http://dx.doi.org/10.1046/j.1365-2249.2000.01125.x
17. Williamson DJ, Begley CG, Vadas MA, Metcalf D. The detection and initial characterization of colony-stimulating factors in synovial fluid. Clin Exp Immunol 1988; 72:67-73; PMID:3260840
18. Xu WD, Firestein GS, Taetle R, Kaushansky K, Zvaifler NJ. Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest 1989; 83:876-82; PMID:2646320; http://dx.doi.org/10.1172/JCI113971
19. Campbell IK, Rich MJ, Bischof RJ, Dunn AR, Grail D, Hamilton JA. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol 1998; 161:3639-44; PMID:9759887
20. Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in Neutropenia. J Immunol 2015; 195:1341-9; PMID:26254266; http://dx.doi.org/10.4049/jimmunol.1500861
21. Benson KF, Li F-Q, Person RE, Albani D, Duan Z, Wechsler J, Meade-White K, Williams K, Acland GM, Niemeyer G, et al. Mutations associated with neutropenia in dogs and humans disrupt intracellular transport of neutrophil elastase. Nat Genet 2003; 35:90-6; PMID:12897784; http://dx.doi.org/10.1038/ng1224
22. Hammond W, Boone T, Donahue R, Souza L, Dale D. A comparison of treatment of canine cyclic hematopoiesis with recombinant human granulocyte-macrophage colony-stimulating factor (GM- CSF), G-CSF interleukin-3, and canine G-CSF. Blood 1990; 76:523-32; PMID:1696146
23. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood 2012; 120:1185-96; PMID:22517900; http://dx.doi.org/10.1182/blood-2011-12-274019
24. Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, Dührsen U, Franzke A, Hallek M, Thiel E, Wilhelm M, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF:a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood 2011; 117:4434-41; PMID:21233311; http://dx.doi.org/10.1182/blood-2010-08-304071
25. Jeng MR, Naidu PE, Rieman MD, Rodriguez-Galindo C, Nottage KA, Thornton DT, Li CS, Wiang WC. Granulocyte-macrophage colony stimulating factor and immunosuppression in the treatment of pediatric acquired severe aplastic anemia. Pediatr Blood Cancer 2005; 45:170-5; PMID:15593082; http://dx.doi.org/10.1002/pbc.20278
26. Forni GFH, Martino F, Hamaoka T, Jemma C, Caretto P, Giovarelli M. Helper strategy in tumor immunology:expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. Cancer Metastasis Rev 1988; 7:289-309; PMID:2974763; http://dx.doi.org/10.1007/BF00051371
27. Forni G, Giovarelli M, Santoni A. Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. J Immunol 1985; 134:1305-11; PMID:3871210
28. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002; 188:147-54; PMID:12445288; http://dx.doi.org/10.1034/j.1600-065X.2002.18813.x
29. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003; 22:3188-92; PMID:12789295; http://dx.doi.org/10.1038/sj.onc.1206459
30. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol 2012; 33:79-84; PMID:23225204; http://dx.doi.org/10.1007/s10875-012-9847-0
31. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90:3539-43; PMID:8097319; http://dx.doi.org/10.1073/pnas.90.8.3539
32. Gridelli C, Rossi A, Maione P, Ferrara ML, Castaldo V, Sacco PC. Vaccines for the treatment of non-small cell lung cancer:A renewed anticancer strategy. Oncologist 2009; 14:909-20; PMID:19726457; http://dx.doi.org/10.1634/theoncologist.2009-0017
33. Yin W, He Q, Hu Z, Chen Z, Qifeng M, Zhichun S, Zhihui Q, Xiaoxia N, Li J, Gao J. A novel therapeutic vaccine of GM-CSF/TNFα surface-modified RM-1 cells against the orthotopic prostatic cancer. Vaccine 2010; 28:4937-44; PMID:20653081; http://dx.doi.org/10.1016/j.vaccine.2010.05.038
34. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, et al. Allogeneic GM-CSF secreting tumor immunotherapy (GVAX(®)) alone or in sequence with cyclophosphamide for metastatic pancreatic cancer:A pilot study of safety, feasibility and immune activation. Clin Cancer Res 2008; 14:1455-63; PMID:18316569; http://dx.doi.org/10.1158/1078-0432.CCR-07-0371
35. Zilberberg J, Friedman TM, Dranoff G, Korngold R. Treatment with GM-CSF secreting myeloid leukemia cell vaccine prior to autologous-BMT improves the survival of leukemia challenged mice. Biol Blood Marrow Transplant 2011; 17:330-40; PMID:20946965; http://dx.doi.org/10.1016/j.bbmt.2010.09.020
36. Zhao F, Dou J, He XF, Wang J, Chu L, Hu W, Yu F, Hu K, Wu Y, Gu N. Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model. Vaccine 2010; 28:2846-52; PMID:20153795; http://dx.doi.org/10.1016/j.vaccine.2010.01.057
37. Clavreul A, Piard N, Tanguy J-Y, Gamelin E, Rousselet M-C, Leynia P, Menei P. Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas. J Clin Neurosci 2010; 17:842-8; PMID:20466548; http://dx.doi.org/10.1016/j.jocn.2009.11.017
38. Zijlmans HJMAA, Fleuren GJ, Baelde HJ, Eilers PHC, Kenter GG, Gorter A. Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-α, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma. Cancer 2007; 109:556-65; PMID:17177206; http://dx.doi.org/10.1002/cncr.22428
39. Driessens G, Hoffmann P, Pouwels M, Zlotta A, Schulman C, Velu T, Bruyns CA. Synergy between dendritic cells and GM–CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma. J Immunother 2009; 32:140-4; PMID:19238012; http://dx.doi.org/10.1097/CJI.0b013e3181920275
40. Simons JW, Nelson W, Nemunaitis J. Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2002; 21:729.
41. Tani K, Azuma M, Nakazaki Y, Oyaizu N, Hase H, Ohata J, Takahashi K, OiwaMonna M, Hanazawa K, Wakumoto Y, et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan:Clinical and immunological findings. Mol Ther 2004; 10:799-816; PMID:15451464; http://dx.doi.org/10.1016/j.ymthe.2004.07.001
42. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nature reviews Immunology 2010; 10:580-93; PMID:20651745; http://dx.doi.org/10.1038/nri2817
43. Hales RK, Banchereau J, Ribas A, Tarhini AA, Weber JS, Fox BA, Drake CG. Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann Oncol 2010; 21:1944-51; PMID:20237004; http://dx.doi.org/10.1093/annonc/mdq048
44. Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57:1537-46; PMID:9108457
45. Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, et al. A live-attenuated listeria vaccine (ANZ-100) and a live-attenuated listeria vaccine expressing mesothelin (CRS-207) for advanced cancers:Phase 1 studies of safety and immune induction. Clin Cancer Res 2012; 18:858-68; PMID:22147941; http://dx.doi.org/10.1158/1078-0432.CCR-11-2121
46. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, et al. Safety and survival with GVAX pancreas prime and listeria monocytogenes–expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 2015; 33:1325-33; PMID:25584002; http://dx.doi.org/10.1200/JCO.2014.57.4244
47. Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, et al. Phase I trial of “bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell” vaccine (FANG) in advanced cancer. Mol Ther 2012; 20:679-86; PMID:22186789; http://dx.doi.org/10.1038/mt.2011.269
48. Phillip B, Maples P, Kumar P, Yu Y, Wang Z, PhD, Jay C, PhD, Pappen BO, Rao DD, PhD, Kuhn J, MD, Nemunaitis J, MD, et al. FANG Vaccine:Autologous tumor cell vaccine genetically modified to express GM-CSF and block production of furin. BioProc J (Winter 2009/2010); 8:4-14
49. Senzer N, Barve M, Nemunaitis J, Kuhn J, Melnyk A, Beitsch P, Magee M, Oh J, Bedell C, Kumar P, Rao DD, et al. Long term follow up:Phase I trial of“bi-shRNA furin/GMCSF DNA/autologous tumor cell” Immunotherapy (FANG™) in advanced cancer. J Vaccines Vaccination 2013; 4:209; http://dx.doi.org/10.4172/2157-7560.1000209
50. Ashley DM, Kong FM, Bigner DD, Hale LP. Endogenous expression of transforming growth factor β1 inhibits growth and tumorigenicity and enhances fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res 1998; 58:302-9; PMID:9443409
51. Ashley DM, Sampson JH, Archer GE, Hale LP, Bigner DD. Local production of TGF β1 inhibits cerebral edema, enhances TNF-α induced apoptosis and improves survival in a murine glioma model. J Neuroimmunol 1998; 86:46-52; PMID:9655471; http://dx.doi.org/10.1016/S0165-5728(98)00017-4
52. Levy L, Hill CS. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006; 17:41-58; PMID:16310402; http://dx.doi.org/10.1016/j.cytogfr.2005.09.009
53. Bierie B, Moses HL. Tumour microenvironment:TGF[beta]:the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6:506-20; PMID:16794634; http://dx.doi.org/10.1038/nrc1926
54. Thorens B, Mermod J-J, Vassalli P. Phagocytosis and inflammatory stimuli induce GM-CSF mRNA in macrophages through posttranscriptional regulation. Cell 1987; 48:671-9; PMID:3102073; http://dx.doi.org/10.1016/0092-8674(87)90245-5
55. Shannon MF, Gamble JR, Vadas MA. Nuclear proteins interacting with the promoter region of the human granulocyte/macrophage colony-stimulating factor gene. Proc Natl Acad Sci U S A 1988; 85:674-8; PMID:3257571; http://dx.doi.org/10.1073/pnas.85.3.674
56. Bickel M, Cohen RB, Pluznik DH. Post-transcriptional regulation of granulocyte-macrophage colony-stimulating factor synthesis in murine T cells. J Immunol 1990; 145:840-5; PMID:2197329
57. Gouy M, Gautier C. Codon usage in bacteria:correlation with gene expressivity. Nucleic Acids Res 1982; 10:7055-74; PMID:6760125; http://dx.doi.org/10.1093/nar/10.22.7055
58. Sharp PM. What can AIDS virus codon usage tell us? Nature 1986; 324:114-; PMID:3641061; http://dx.doi.org/10.1038/324114a0
59. Bennetzen JL, Hall BD. Codon selection in yeast. J Biol Chem 1982; 257:3026-31; PMID:7037777
60. Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N. A “humanized” green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 1996; 70:4646-54; PMID:8676491
61. zur Megede J, Chen M-C, Doe B, Schaefer M, Greer CE, Selby M, Otten GR, Barnett SW. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J Virol 2000; 74:2628-35; PMID:10684277; http://dx.doi.org/10.1128/JVI.74.6.2628-2635.2000
62. Qiu J-T, Chang T-C, Lin C-T, Chen Y-M, Li FQ, Soong Y-K, Lai CH. Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 Gag. Vaccine 2007; 25:253-63; PMID:16971027; http://dx.doi.org/10.1016/j.vaccine.2006.07.034
63. Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol Gene. J Virol 2000; 74:4839-52; PMID:10775623; http://dx.doi.org/10.1128/JVI.74.10.4839-4852.2000
64. Haas J, Park E-C, Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996; 6:315-24; PMID:8805248; http://dx.doi.org/10.1016/S0960-9822(02)00482-7
65. Warren TL, Weiner GJ. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol 2000; 7:168-73; PMID:10786654; http://dx.doi.org/10.1097/00062752-200005000-00007
66. Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, Ramanathan MP, Parkinson R, Kudchodkar S, Tamura Y, et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 2005; 175:112-23; PMID:15972637; http://dx.doi.org/10.4049/jimmunol.175.1.112
67. Hsu C, Hughes MS, Zheng Z, Bray RB, Rosenberg SA, Morgan RA. Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol (Baltimore, Md:1950) 2005; 175:7226-34; PMID:16301627; http://dx.doi.org/10.4049/jimmunol.175.11.7226
68. Lin C-C, Tsai C-C, Lee J-M, Fang C-H, Chang K-S, Wong K-K, Lin CT, Qiu JT. The efficacy of a novel vaccine approach using tumor cells that ectopically express a codon-optimized murine GM-CSF in a murine tumor model. Vaccine 2016; 34:134-41; PMID:26546261; http://dx.doi.org/10.1016/j.vaccine.2015.10.106
69. Lang RA, Metcalf D, Cuthbertson RA, Lyons I, Stanley E, Kelso A, Kannourakis G, Williamson DJ, Klintworth GK, Gonda TJ, et al. Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell 1987; 51:675-86; PMID:3499986; http://dx.doi.org/10.1016/0092-8674(87)90136-X
70. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90:3539-43; PMID:8097319; http://dx.doi.org/10.1073/pnas.90.8.3539
71. Parker SE, Monteith D, Horton H, Hof R, Hernandez P, Vilalta A, Hartikka J, Hobart P, Bentley CE, Chang A, et al. Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine. Gene Ther 2001; 8:1011-23; PMID:11438836; http://dx.doi.org/10.1038/sj.gt.3301491
72. Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, Jackson SS, Lifton MA, Freed DC, Perry HC, et al. Potent CD4+ T Cell Responses Elicited by a Bicistronic HIV-1 DNA Vaccine Expressing gp120 and GM-CSF. J Immunol 2002; 168:562-8; PMID:11777947; http://dx.doi.org/10.4049/jimmunol.168.2.562
73. Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57:1537-46; PMID:9108457
74. Mastrangelo MJ, Maguire HC, Jr., Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ, Lattime EC. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999; 6:409-22; PMID:10505851; http://dx.doi.org/10.1038/sj.cgt.7700066
75. Simons JW, Mikhak B, Chang J-F, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, et al. Induction of immunity to prostate cancer antigens:Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59:5160-8; PMID:10537292
76. Chang AE, Li Q, Bishop DK, Normolle DP, Redman BD, Nickoloff BJ. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Human Gene Ther 2000; 11:839-50; PMID:10779161; http://dx.doi.org/10.1089/10430340050015455
77. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non–small-cell lung carcinoma. J Clin Oncol 2003; 21:624-30; PMID:12586798; http://dx.doi.org/10.1200/JCO.2003.03.091
78. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21:3343-50; PMID:12947071; http://dx.doi.org/10.1200/JCO.2003.07.005
79. Nemunaitis J, Sterman D, Jablons D, Smith JW, Fox B, Maples P, Hamilton S, Borellini F, Lin A, Morali S, et al. Granulocyte–macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non–small-cell lung cancer. J Natl Cancer Inst 2004; 96:326-31; PMID:14970281; http://dx.doi.org/10.1093/jnci/djh028
80. Luiten RM, Kueter EWM, Mooi W, Gallee MPW, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF–transduced tumor cells in metastatic melanoma patients. J Clin Oncol 2005; 23:8978-91; PMID:16260696; http://dx.doi.org/10.1200/JCO.2005.01.6816
81. Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S, et al. Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-Naïve Prostate Cancer. Clin Cancer Res 2006; 12(11):3394-3401; http://dx.doi.org/10.1158/1078-0432.CCR-06-0145
82. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, et al. Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer:A Pilot Study of Safety, Feasibility, and Immune Activation. Clin Cancer Res 2008; 14(5):1455-1463; http://dx.doi.org/10.1158/1078-0432.CCR-07-0371
83. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor–secreting breast tumor vaccine:A chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009; 27:5911-8; PMID:19805669; http://dx.doi.org/10.1200/JCO.2009.23.3494
84. van den Eertwegh AJM, Versluis J, van den Berg HP, Santegoets SJAM, van Moorselaar RJA, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer:a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:509-17; PMID:22326922; http://dx.doi.org/10.1016/S1470-2045(12)70007-4
85. Vuky J, Corman JM, Porter C, Olgac S, Auerbach E, Dahl K. Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer. Oncologist 2013; 18:687-8; PMID:23740935; http://dx.doi.org/10.1634/theoncologist.2011-0234
86. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, et al. Safety and survival with GVAX pancreas prime and listeria monocytogenes–expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 2015; 33:1325-33; PMID:25584002; http://dx.doi.org/10.1200/JCO.2014.57.4244
87. Lipson EJ, Sharfman WH, Chen S, McMiller TL, Pritchard TS, Salas JT, Sartorius-Mergenthaler S, Freed I, Ravi S, Wang H, et al. Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J Transl Med 2015; 13; PMID:26143264; http://dx.doi.org/10.1186/s12967-015-0572-3